Open AccessAntitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16)
Author(s) -
Seonggyu Byeon,
Myoung Joo Kang,
Yoon Ji Choi,
Yu Jung Kim,
Miso Kim,
Jina Yun,
Seong Yoon Yi,
Jin Young Kim,
Seung Tae Kim,
Jeeyun Lee
Publication year - 2020
Publication title -
translational cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.254
H-Index - 30
eISSN - 2219-6803
pISSN - 2218-676X
DOI - 10.21037/tcr.2020.04.07
Subject(s) - sirolimus , medicine , adverse effect , progressive disease , chemotherapy , oncology , pi3k/akt/mtor pathway , refractory (planetary science) , everolimus , response evaluation criteria in solid tumors , surgery , gastroenterology , biology , apoptosis , biochemistry , astrobiology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom